Literature DB >> 25692059

Cryptococcus laurentii Diarrhea in a Neoplastic Patient.

Franco Calista1, Federica Tomei1, Pasquale Assalone1, Divina Traficante1, Gianni Di Pilla2, Carla Pepe3, Liberato Di Lullo1.   

Abstract

We present a rare case of diarrhea and neutropenia caused by Cryptococcus laurentii (C. laurentii) infection in old patient with metastatic rectal cancer who underwent FOLFOX plus Cetuximab chemotherapy. C. laurentii is an extremely rare human pathogen. To the best of our knowledge, here, we report the first case of diarrhea and neutropenia caused by C. laurentii in a 74-year-old man with metastatic rectal cancer and hepatic metastases who underwent FOLFOX plus Cetuximab chemotherapy.

Entities:  

Year:  2015        PMID: 25692059      PMCID: PMC4323062          DOI: 10.1155/2015/216458

Source DB:  PubMed          Journal:  Case Rep Oncol Med


1. Introduction

C. laurentii is a rare human pathogen. This fungus was previously considered saprophytic and nonpathogenic to humans, but it has been isolated as the etiologic agent of skin infection, keratitis, endophthalmitis, lung abscess, peritonitis, meningitis, and fungemia [1, 2]. To the best of our knowledge the present report is the first to describe isolation of C. laurentii from human stool and this is the first reported isolation of C. laurentii in neoplastic patient's stool. We present the case of a 74-year-old man who undergoes FOLFOX plus Cetuximab chemotherapy due to metastatic rectal cancer.

2. Case Report

We present the case of a 74-year-old Caucasian man with rectal cancer and hepatic metastases, severe carotid stenosis, and chronic hepatitis B. He smoked for forty years and quit twenty years ago. In December 2013 the patient underwent colonoscopy and total body computed tomography scan. Histopathological and molecular examination showed a rectal adenocarcinoma with K-ras and N-ras wild type. In January 2014 FOLFOX plus Cetuximab chemotherapy was started. After the fifth cycle of chemotherapy the patient was admitted with nausea, vomit, and diarrhea. Systemic examination showed no fever or hypotension and dyspnoea. Blood test revealed an electrolyte imbalance. A chest X-ray showed right lower lobe pneumonia (Figure 1). Patient was empirically put on a third-generation cephalosporin plus ciprofloxacin; loperamide, rifaximin, and rehydration therapy were also initiated. On third day of admission laboratory investigations reported G1 leucopenia: white blood cell count: 3.310 K/μL (reference range 4.0–10.0) and G2 neutropenia: neutrophil cell count: 1.240 K/μL (reference range 2.5–7.5) and G2 anemia: haemoglobin: 8.0 g/dL (reference range 13.5–17.5). C. laurentii (+++) was isolated from stool culture on the seventh day of admission. At this point, lipid formulation of amphotericin B (AmBisome) 3 mg/Kg was started and continued for ten days. Anamnesis revealed that the patient had a goldfinch to which he attended every day. Echocardiogram, HIV test, and eye examination were performed with negative result. During treatment with lipid formulation of amphotericin B (AmBisome) we noticed a gradual improvement in leukoneutropenia up to the normalization of the values and disappearance of diarrhea. After ten days a stool culture for fungus and a chest X-ray were repeated with negative result (Figure 2). On the eighteenth day of admission the patient was discharged in good health. After one week the patient has continued FOLFOX plus Cetuximab chemotherapy without side effects.
Figure 1

Chest X-ray at the admission.

Figure 2

Chest X-ray after lipid formulation of amphotericin B therapy.

3. Discussion

C. laurentii is a rare human pathogen. This fungus was previously considered saprophytic and not pathogenic to humans [1]. In the last few years there has been an increasing incidence of C. laurentii infection due to a growing population of immunosuppressed patients. C laurentii, a basidiomycetous encapsulated yeast, is present in the droppings and cloacal samples of feral birds, such as pigeons. Our patient had a goldfinch to which he attended every day. C. laurentii is responsible for both deep seated infections, such as fungemia and meningitis, and superficial infections such as keratitis [3]. Generally C. laurentii infection clinically presents with febrile illness, hypotension, cardiac valvular involvement, and choroidal infection and endophthalmitis [4, 5]. Our patient was admitted with diarrhea, and he had no fever or hypotension. Subramanian and Mathai [6] showed that the lung is most probably the initial portal of entry in immunocompromised patients. In our case, total body computed tomography performed before chemotherapy showed no pneumonia. After the isolation of C. laurentii in stool culture echocardiogram and eye examination were performed because cardiac valvular involvement, mycotic aneurysms, myocarditis, and endocarditis due to C. laurentii have been published. Our patient also underwent HIV test because Cryptococcosis is the first opportunistic infection that occurs in over a quarter of patients who develop AIDS [2, 6]. To the best of our knowledge the present report is the first to describe isolation of C. laurentii from human stool. Our patient was admitted with diarrhea and presented no chemotherapy-related neutropenia during admission.
  6 in total

Review 1.  Cryptococcal endophthalmitis: case report and review.

Authors:  J R Crump; S G Elner; V M Elner; C A Kauffman
Journal:  Clin Infect Dis       Date:  1992-05       Impact factor: 9.079

2.  Cryptococcus neoformans endocarditis cured by amphotericin B.

Authors:  R A Colmers; W Irniger; D H Steinberg
Journal:  JAMA       Date:  1967-03-06       Impact factor: 56.272

3.  Cutaneous Cryptococcus laurentii infection in an immunocompetent child.

Authors:  Alejandro Molina-Leyva; Jose C Ruiz-Carrascosa; Ana Leyva-Garcia; Husein Husein-Elahmed
Journal:  Int J Infect Dis       Date:  2013-06-19       Impact factor: 3.623

Review 4.  Clinical manifestations and management of cryptococcal infection.

Authors:  S Subramanian; D Mathai
Journal:  J Postgrad Med       Date:  2005       Impact factor: 1.476

5.  Cryptococcus laurentii fungemia.

Authors:  P Banerjee; M Haider; V Trehan; B Mishra; A Thakur; V Dogra; P Loomba
Journal:  Indian J Med Microbiol       Date:  2013 Jan-Mar       Impact factor: 0.985

Review 6.  Non-neoformans cryptococcal infections: a systematic review.

Authors:  T Khawcharoenporn; A Apisarnthanarak; L M Mundy
Journal:  Infection       Date:  2007-04       Impact factor: 3.553

  6 in total
  4 in total

Review 1.  Clinical diversity of invasive cryptococcosis in AIDS patients from central China: report of two cases with review of literature.

Authors:  Yongxi Zhang; Brian Cooper; Xi'en Gui; Renslow Sherer; Qian Cao
Journal:  BMC Infect Dis       Date:  2019-11-27       Impact factor: 3.090

Review 2.  Anti-Fungal Efficacy and Mechanisms of Flavonoids.

Authors:  Mohammed Saleh Al Aboody; Suresh Mickymaray
Journal:  Antibiotics (Basel)       Date:  2020-01-26

3.  First case report of Cryptococcus laurentii knee infection in a previously healthy patient.

Authors:  Hetao Huang; Jianke Pan; Weiyi Yang; Jiongtong Lin; Yanhong Han; Kai Lan; Lingfeng Zeng; Guihong Liang; Jun Liu
Journal:  BMC Infect Dis       Date:  2020-09-17       Impact factor: 3.090

4.  Catheter-related infection due to Papiliotrema laurentii in an oncologic patient: Case report and systematic review.

Authors:  Marcos Rech Londero; Crisley Dossin Zanrosso; Leandro Luis Corso; Lessandra Michelin; Jonathan Soldera
Journal:  Braz J Infect Dis       Date:  2019-11-16       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.